Centrum Medyczne Plejady Magdalena Celinska Loewenhoff Michal Zolnowski sp.k.
- Address
- lock Available on a paid plan
Inflammatory Bowel Disease Research
The gastroenterology department at Centrum Medyczne Plejady focuses on Inflammatory Bowel Disease, testing new therapeutic approaches aimed at achieving clinical remission and improving quality of life for patients.
- Crohn's disease – evaluation of novel biologics and small molecules
- Ulcerative colitis – assessment of induction and maintenance strategies
- Endoscopic response as a marker of treatment success
- Patient‑reported outcomes for disease activity
With a robust portfolio of 84 trials, the site collaborates with investigators to advance care for individuals living with chronic intestinal inflammation.
Autoimmune and Systemic Disease Trials
Research at the center targets autoimmune and systemic disorders, seeking to modulate immune pathways and reduce disease burden across a spectrum of conditions.
- Systemic lupus erythematosus – testing targeted immunomodulators
- Sjögren’s syndrome – improving glandular function and systemic symptoms
- Systemic sclerosis – evaluating antifibrotic agents
- Biomarker‑driven patient selection for personalized therapy
The department’s multidisciplinary team leverages its experience to explore long‑term safety and efficacy of emerging treatments.
Dermatology and Skin Research
The clinic conducts trials in dermatology to address inflammatory and chronic skin conditions, aiming to provide patients with more effective and tolerable options.
- Psoriatic arthritis – comparative studies of biologic agents
- Atopic dermatitis – long‑term safety of biologics in children
- Acne vulgaris – topical therapies for sustained clearance
- Chronic spontaneous urticaria – novel antihistamine‑refractory treatments
Participants benefit from state‑of‑the‑art assessments of disease activity and quality‑of‑life measures.
Neurology and Movement Disorder Studies
Investigations in the neurological field focus on migraine, Parkinson's disease, and epilepsy, evaluating new drugs and delivery methods to lessen symptom severity and improve daily functioning.
- Migraine – preventive and acute therapies for adolescents
- Parkinson's disease – agents targeting tremor and disease progression
- Dravet syndrome – adjunctive treatments to reduce seizure frequency
- Lennox‑Gastaut syndrome – combination therapies for refractory seizures
The site’s neurologic expertise supports rigorous safety monitoring and functional outcome assessments.
Allergy and Respiratory Research
Trials address allergic rhinitis and related respiratory conditions, testing immunotherapy and symptom‑relief strategies for seasonal and perennial triggers.
- Birch pollen‑induced allergic rhinoconjunctivitis – sublingual immunotherapy efficacy
- Grass pollen allergy – pediatric safety and long‑term benefit
- Seasonal allergic rhinitis – quality‑of‑life impact
- H1 antihistamine‑refractory chronic urticaria – novel biologic options
By integrating allergen challenge models, the center contributes valuable data on disease control across age groups.
Cardiovascular and Metabolic Trials
The facility also explores cardiovascular and metabolic health, aiming to lower risk factors and improve outcomes for patients with established disease.
- Atherosclerotic cardiovascular disease – LDL‑cholesterol lowering interventions
- Obesity – lifestyle‑adjunct pharmacologic studies
- Metabolic syndrome – combined therapy assessments
- Cardiovascular event reduction – long‑term safety monitoring
The research integrates cardiovascular endpoints with metabolic parameters to provide a comprehensive view of patient health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 12 therapeutic areas and 15 of 122 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 120 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 29 by active trials.
- 1Janssen Cilag International5active
lock +28 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International12trials
lock +22 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Medyczne Plejady Magdalena Celinska Loewenhoff Michal Zolnowski sp.k.
lock Showing 1 of 112 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus | Bristol Myers Squibb International Corporation | Phase II | Not Recruiting | May 2019 | Mar 2025 |
IMP list
lock Showing 1 of 122 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Guselkumab | 9 | Unknown | 2018-07-26 | 2026-05-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
